Humanized mice (target-specific)

Well-established mouse lines that allow in vivo efficacy and safety assessment of biologics and other compounds.

Applications

These models are suitable to assess the efficacy of compounds targeting human proteins in fully immunocompetent mice. Moreover, they represent a powerful model system for studying how compounds modulate cell response and/or stroma cells in a physiological microenvironment.

General model features

  • Physiological expression of the human target(s)
  • Preservation of the target-ligand interaction
  • Fully functional mouse immune system
  • Lack of expression of the murine target gene, thus avoiding cross-reactivity

Discover our

Humanized mice (target-specific)

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

hCD4

The human CD4 mouse model allows in vivo efficacy and safety assessment of anti-human CD4 compounds.

CD4
Inflammation
T-cell receptor

Pan hCD3

Pan hCD3 immunocompetent mice enable the efficacy assessment of T-cell engagers, to study cancer cell recognition, immunosuppressant therapies, etc.

T-cell engager
CD3

hVISTA

The hVISTA mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint VISTA in fully immunocompetent mice.

Immune checkpoint
VISTA
ICP (single-target)

hPD-1

The hPD-1 mouse enables the in vivo efficacy assessment and profiling of compounds targeting the human immune checkpoint PD-1 in fully immunocompetent mice

PD-1
Immune checkpoint
ICP (single-target)

hFcγR

Preclinical humanized Fc-gamma receptor (hFcγR) model enabling the assessment of Fc receptor pathways targeted therapies.

FcgR
Fc receptor

HSA/hFcRn

Double humanized HSA-hFcRn mouse model as a cutting-edge platform for preclinical development of HSA and FcRn-oriented therapeutics.

HSA
PK/PD
Fc receptor

hTFRC

The fully immunocompetent hTFRC mouse model enables in vivo efficacy assessment and profiling of compounds targeting human TFRC (CD71, TfR1) and aiming to deliver therapeutic agents through the blood brain barrier.

TFRC
Drug shuttling

hCD3ε/hCD28

hCD3ε  immunocompetent mice enable the efficacy assessment of T-cell engagers, to  study cancer cell recognition, immunosuppressant therapies, etc.

CD3
CD28
T-cell engager

hGLP-1R

Preclinical hGLP-1R model for assessment of agents targeting human GLP-1R

GLP-1R
Metabolism

HSA/hFcRn-Rag1-KO

This upgraded, immunocompromised Rag1-/- version of our HSA/hFcRn mouse model allows the assessment of compounds' half-life and anti-tumor efficacy in a human tumor model.

HSA
PK/PD
Fc receptor
KO-Rep-Mix

hPD-1/hGITR/hGITRL

The hPD-1/hGITR/hGITRL mouse model enables in vivo efficacy assessment and profiling of antibodies targeting human immune checkpoint PD-1, GITR and/or GITRL in fully immunocompetent mice.

Immune checkpoint
PD-1
GITR
ICP (multi-target)
GITRL

hCD28

The hCD28 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint CD28 in fully immunocompetent mice.

Immune checkpoint
CD28
ICP (single-target)
T-cell engager

hIgE/hFcεR1

Use the hIgE/hFcεR1 mouse model to successfully screen for innovative therapeutics for allergy, asthma and other IgE-mediated diseases.

Inflammation
IgE
FceR1
Fc receptor
Allergy

hCD3ε

hCD3ε immunocompetent mice enable the preclinical in vivo efficacy assessment of T-cell engagers, to study cancer cell recognition, immunosuppressant therapies, etc.

T-cell engager
CD3

hCTLA-4/hLAG3

The hCTLA-4/hLAG3 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint CTLA-4 and/or LAG3 in fully immunocompetent mice.

Immune checkpoint
CTLA-4
Lag3
ICP (multi-target)

hPD-1/hCTLA-4

The hPD-1/hCTLA-4 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint PD-1 and/or CTLA-4 in fully immunocompetent mice.

Immune checkpoint
CTLA-4
PD-1
ICP (multi-target)

hGITR/hGITRL

The hGITR/hGITRL mouse model enables in vivo efficacy assessment and profiling of agonist and antagonist antibodies targeting human immune checkpoint GITR and/or GITRL in fully immunocompetent mice.

Immune checkpoint
GITR
GITRL
ICP (multi-target)

hPD-1/hTIM3

The hPD-1/hTIM3 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint PD-1 and/or TIM3 in fully immunocompetent mice.

Immune checkpoint
PD-1
TIM3
ICP (multi-target)

hPD-1/hVISTA

The hPD-1/hVISTA mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint PD-1 and/or VISTA in fully immunocompetent mice.

Immune checkpoint
PD-1
VISTA
ICP (multi-target)

hPD-1/hLAG3

The hPD-1/hLAG3 mouse model enables in vivo efficacy assessment and profiling of antibodies targeting human immune checkpoint PD-1 and/or LAG3 in fully immunocompetent mice.

Immune checkpoint
PD-1
Lag3
ICP (multi-target)

hPD-1/hPD-L1

The hPD-1/hPD-L1 mouse model enables in vivo efficacy assessment and profiling of molecules targeting the human PD-1/PD-L1 axis in fully immunocompetent mice.

Immune checkpoint
PD-1
PD-L1
ICP (multi-target)

hCD39

The hCD39 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint CD39 in fully immunocompetent mice.

Immune checkpoint
CD39
ICP (single-target)

hCTLA-4

The hCTLA-4 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint CTLA-4 in fully immunocompetent mice.

Immune checkpoint
CTLA-4
ICP (single-target)

hGITR

The hGITR mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint GITR in fully immunocompetent mice.

Immune checkpoint
GITR
ICP (single-target)

hOX40

The hOX40 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint OX40 in fully immunocompetent mice.

Immune checkpoint
OX40
ICP (single-target)

hSTING

The hSTING mouse enables the in vivo assessment of agents and therapies targeting the human STING in fully immunocompetent mice.

STING
cGAS-STING pathway

hTNF-α

The hTNF-α model provides new opportunities for assessment of anti-TNF therapies.

Inflammation
TNF
Cytokine

hcGAS

The hcGAS mouse enables the in vivo assessment of agents and therapies targeting the cGAS–STING cytosolic DNA sensing pathway in fully immunocompetent mice.

cGAS
cGAS-STING pathway

Discover our customized models

Learn  more

Related resources and publications

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No results